Importantly, the dysregulation of HDAC activity has emerged as a significant player in the pathogenesis of PAH, and a study found promising therapeutic outcomes using small-molecule HDAC inhibitors in diverse animal models of PAH [167]. The gene discussed is HDAC9; the disease is pulmonary arterial hypertension.